The HHS peptide policy takes public comments until about November 13, 2026, and you file them on regulations.gov under docket HHS-OASH-2026-0496. The Federal Register notice sets the window at two weeks after its October 30, 2026 publication. The Hone Health blog, a telehealth company’s post, gives November 13 as that date. HHS issued and filed the policy on October 28, 2026. It is an interim enforcement-discretion policy covering six peptides (BPC-157, TB-500, KPV, epitalon, Semax and MOTS-c), and it is not an FDA approval of any of them.
Quick facts, as of 2026-11-11
| Item | Detail |
|---|---|
| Policy | HHS interim enforcement-discretion policy on 503A compounding with six peptides (HHS policy document) |
| Issued and filed | October 28, 2026 (HHS policy document; Federal Register notice filed at 11:15 am) |
| Federal Register publication | October 30, 2026 (Federal Register notice 2026-22192) |
| Docket | HHS-OASH-2026-0496, on regulations.gov |
| Comment window | Open until two weeks after Federal Register publication (notice wording) |
| Deadline date | About November 13, 2026 (Hone Health blog’s figure) |
| Six peptides | BPC-157, TB-500, KPV, epitalon, Semax, MOTS-c |
| Status on the 503A bulks list | Pending FDA rulemaking, with no announced deadline (Hone Health blog; Fierce Pharma) |
| Who it covers | State-licensed pharmacies, Federal facilities and licensed physicians compounding with a patient-specific prescription (HHS policy document) |
What is the HHS peptide policy?
The policy comes from the Department of Health and Human Services. Its own wording says HHS “does not intend to take enforcement action against a State-licensed pharmacy, Federal facility, or licensed physician” that compounds a drug with a listed bulk substance, when every listed condition is met. Compounding means a pharmacy or doctor mixing a drug for one patient. The policy is framed under section 503A, which covers patient-specific compounding by pharmacies and physicians. You can read it in the HHS enforcement discretion policy.
HHS gives its reason as “significant interest in the use of these peptides in compounding.” It also says the policy “advances patient choice and freedom while appropriately protecting patient safety.” HHS adds that it will discourage “the continued, widespread use of certain research-use-only peptides supplied by foreign manufacturers that pose a safety risk to US patients.”
The Federal Register notice 2026-22192 is signed by Robert F. Kennedy, Jr., Secretary. Its background section calls the document a “draft” policy, while the HHS document calls it an interim policy. The notice says future FDA rulemaking “may propose adding some or all of these peptides to the 503A bulks list based on the available evidence.”
Which six peptides does the policy cover?
The policy names six substances. The table shows the forms the Hone Health blog lists, which it says come from the HHS appendix, and the uses Reuters attaches to each peptide.
| Peptide | Forms Hone Health lists | Uses or context in press coverage |
|---|---|---|
| BPC-157 | Injection, oral or topical | Covered on its own; Reuters calls it part of the “Wolverine stack” pairing with TB-500, but a blended product is not covered because HHS limits products to one active ingredient |
| TB-500 | Injection | Covered on its own; Reuters calls it part of the “Wolverine stack” pairing with BPC-157, but a blended product is not covered because HHS limits products to one active ingredient |
| KPV | Oral or topical | Wound healing and inflammatory conditions (Reuters’s description) |
| Epitalon | Injection in intermittent courses | Insomnia (Reuters’s description) |
| Semax | Nasal | Migraines and chronic pain (Reuters’s description) |
| MOTS-c | Injection | Obesity and osteoporosis (Reuters’s description) |
The policy allows one active ingredient per product. The Los Angeles Times reports that it prohibits compounding peptide combinations. So a blended vial, such as the “Wolverine stack” pairing, falls outside the policy, as Hone Health reads it.
Key dates
| Date | What happened | Source |
|---|---|---|
| July 2026 | FDA’s Pharmacy Compounding Advisory Committee recommended that all six be allowed in compounding | Reuters, October 28, 2026 |
| October 28, 2026 | HHS issued and filed the policy. Reuters and Fierce Pharma call it Wednesday’s policy. | HHS policy document; Federal Register notice |
| October 30, 2026 | Published in the Federal Register | Federal Register notice 2026-22192 |
| About November 13, 2026 | Comment window closes, two weeks after publication | Federal Register notice; Hone Health blog’s figure |
| Before the end of February 2027 | FDA plans an outside expert panel on five more peptides: LL-37, GHK-Cu, dihexa acetate, melanotan II and PEG-MGF | Hone Health blog, citing an FDA advisory-committee page |
How do I comment on the HHS peptide policy?
- Go to regulations.gov and search for docket HHS-OASH-2026-0496.
- Submit your written comment by about November 13, 2026. The notice accepts comments until two weeks after the October 30 Federal Register publication.
- Read the notice first. The Federal Register notice 2026-22192 names Victoria Marshall, Office of the Assistant Secretary for Health, as its contact.
HHS says public comments “may provide additional evidence that FDA can consider in rulemaking.” HHS also says it may revisit the policy, in whole or in part, if a safety signal or product quality issue arises with a compounded product in scope. With the window closing around November 13, the time left is short.
Who does the policy affect?
- Pharmacies and doctors: State-licensed pharmacies, Federal facilities and licensed physicians, under HHS’s wording.
- Patients: a patient-specific prescription is required, according to HHS’s background section and Hone Health.
- Outsourcing facilities: Hone Health says the policy does not cover 503B outsourcing facilities.
- State rules: Hone Health says state pharmacy boards can still restrict access. Reuters quotes Jeff Cohen, co-founder of the American Peptide Association, saying states may not follow the federal policy.
- Start date: Scott Brunner, CEO of the Alliance for Pharmacy Compounding, lists when the policy takes effect as an open question (Fierce Pharma).
Who supports and who criticizes the policy?
| Name and role | Position | What they said |
|---|---|---|
| Robert F. Kennedy, Jr., HHS Secretary | Signed the policy | Reuters reports he calls himself a “big fan” of peptides. HHS says the policy “advances patient choice and freedom while appropriately protecting patient safety.” |
| Robert Steinbrook, director, Public Citizen’s Health Research Group | Critic (advocacy group) | Says Kennedy acted “recklessly and unilaterally,” and that the policy could expose patients to contamination, impurities and unknown side effects. He says peptides should go through standard FDA approval (Reuters, October 28, 2026). |
| Patricia Zettler, professor, Ohio State’s Moritz College of Law; former FDA attorney | Critic | “What it does is allow companies to profit without proving that their products work.” She says it is highly unusual that the policy came from HHS and not FDA (Los Angeles Times, November 11, 2026). |
| Dr. Pieter Cohen, associate professor of medicine, Harvard Medical School | Critic | Says “FDA’s role has completely reversed to be one of facilitating this type of magical thinking and promotion of the untested and unproven” (Los Angeles Times). |
| Scott Brunner, CEO, Alliance for Pharmacy Compounding (trade group) | Supporter | Welcomed the decision as a “more accountable alternative” to illicit suppliers. He listed open questions on when the policy takes effect, how API testing will be validated and how utilization reporting will work (Fierce Pharma, October 29, 2026). |
| Lee Rosebush, chair, American Academy of Peptide Medicine | Supporter | Called it a “landmark regulatory milestone” (Reuters). |
| Jeff Cohen, co-founder, American Peptide Association | Raises a state-federal concern | Said the policy could amplify tension between federal and state regulators, because states may not follow (Reuters). |
| Hanieh Sigari, founder and CEO, EllieMD (telehealth company) | Supporter | “You can’t ignore the anecdotal evidence” (Los Angeles Times). |
| Elizabeth Yurth, M.D., Hone-affiliated physician | Supporter | Testified in July in support of compounding access to BPC-157 and TB-500, according to the Hone Health blog. |
Has the FDA approved BPC-157?
The answer is no. The Los Angeles Times reports that FDA has approved BPC-157 for human use in no form. The same is true of TB-500 and injectable GHK-Cu. Fierce Pharma says the advisory committee’s votes are recommendations, and the six peptides “still haven’t been added to the drug substances list.”
Most research on the six has been in animals or cells and tissues, and the LA Times says the quality of that evidence varies. It also says no data exist on how different peptides interact in “stacks.” For a plain-language look at what studies have measured, see peptides safety evidence (our research library). Which measure a study uses matters, as a procedure claims cartilage regrowth explains for joint claims.
What is the risk of taking peptides?
HHS’s own policy document says: “Compounded drugs are not FDA-approved, which means FDA does not review their safety, effectiveness, or quality before they are marketed.” It adds that compounded drugs “also may pose risks to patients.” The conditions below are HHS’s safeguards.
| Condition | What HHS requires, in summary |
|---|---|
| Ingredient source | Bulk substance from an FDA section 510 registered facility, with a certificate of analysis (COA) showing identity, purity, potency and no contaminants such as endotoxins, heavy metals or microbes |
| Manufacturer | The original manufacturer is FDA-registered and CGMP (current good manufacturing practice) compliant. Repackers and resellers need documented vendor validation. |
| Reporting | Compounders report serious adverse events and product quality issues to FDA MedWatch and to the states |
| Label | “This is a compounded drug product. Not for resale.” |
| Ingredients | One active ingredient from the six listed substances |
| Oral forms | Documentation that the formulation achieves adequate oral bioavailability in humans. HHS calls achieving that “inherently difficult and complex.” |
| Syringe | The only co-packaged delivery device is an FDA 510(k)-cleared syringe |
| Prescription | A patient-specific prescription |
Public Citizen’s Robert Steinbrook says the policy could expose patients to contamination, impurities and unknown side effects (Reuters, October 28, 2026).
Oral and sublingual forms raise a separate question. The Los Angeles Times reports that most peptides break down in the digestive tract, and that enzymes and acids destroy TB-500 before it leaves the intestine. It cites Croatian researchers who found preliminary evidence that BPC-157 survives in the gut. It also says there has been no published research on whether BPC-157 or TB-500 work sublingually.
Common mix-ups
- “Legal” headlines: Hone Health says the policy “doesn’t legalize these peptides or grant FDA approval.”
- Research-use-only products: HHS says the policy aims to discourage research-use-only peptides from foreign manufacturers. It covers pharmacies and physicians compounding from FDA-registered sources under prescriptions. Research-use-only vials and sublingual strips sold online are outside that scope.
- Wolverine stack: the single-ingredient rule means a blended BPC-157 and TB-500 vial falls outside the policy.
- GHK-Cu: it is one of the peptides in the FDA panel plan, but it is outside the six covered here.
- 503A and 503B: the policy is framed under 503A. Hone Health says 503B outsourcing facilities are not covered.
- Dates: Reuters and Fierce Pharma say Wednesday, October 28, which matches HHS’s issue date. The Federal Register publication date is October 30.
- Draft or interim: the Federal Register notice says “draft,” and the HHS document says interim.
- Read a claim against its evidence: a maker’s claim is not a study result. recovery claims after a procedure shows how to separate the two.
Questions to settle your next step
- Do you want to comment? File at regulations.gov under docket HHS-OASH-2026-0496 before about November 13, 2026.
- Ask your prescriber whether any of these six fits your situation. Ask a pharmacist whether a compounding pharmacy near you offers any of them and when.
- Ask the pharmacy whether its ingredient comes from an FDA-registered facility with a certificate of analysis.
- Ask whether the product contains one active ingredient and carries the label “This is a compounded drug product. Not for resale.”
- Ask how your state pharmacy board handles these substances, since the board can still restrict access.
By the Regenerative Evidence Guide Team
This article is for general information purposes only and does not constitute medical advice. Consult your doctor or qualified healthcare provider before making changes to your health routine.
Leave a Reply